Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
F 0.72 -2.95% -0.02
CHRS closed down 2.95 percent on Friday, November 1, 2024, on 82 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 6
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -2.95%
Oversold Stochastic Weakness -2.95%
Wide Bands Range Expansion -3.59%
Oversold Stochastic Weakness -3.59%
New Downtrend Bearish -2.74%
New 52 Week Low Weakness -2.74%
Wide Bands Range Expansion -2.74%

   Recent Intraday Alerts

Alert Time
Outside Day about 18 hours ago
Down 3% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
Down 2 % about 18 hours ago
Down 1% about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coherus BioSciences, Inc. Description

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Chemotherapy Treatment Of Breast Cancer Psoriasis Rheumatoid Arthritis Immunosuppressants Biosimilar Recombinant Proteins Adalimumab Neutropenia

Is CHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.73
52 Week Low 0.71
Average Volume 2,274,030
200-Day Moving Average 1.76
50-Day Moving Average 1.06
20-Day Moving Average 0.87
10-Day Moving Average 0.78
Average True Range 0.07
RSI (14) 26.47
ADX 29.79
+DI 11.16
-DI 29.63
Chandelier Exit (Long, 3 ATRs) 1.03
Chandelier Exit (Short, 3 ATRs) 0.91
Upper Bollinger Bands 1.08
Lower Bollinger Band 0.66
Percent B (%b) 0.16
BandWidth 48.82
MACD Line -0.10
MACD Signal Line -0.09
MACD Histogram -0.0034
Fundamentals Value
Market Cap 80.52 Million
Num Shares 111 Million
EPS -2.55
Price-to-Earnings (P/E) Ratio -0.28
Price-to-Sales 1.46
Price-to-Book 73.19
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.80
Resistance 3 (R3) 0.80 0.78 0.78
Resistance 2 (R2) 0.78 0.76 0.78 0.78
Resistance 1 (R1) 0.75 0.75 0.74 0.75 0.78
Pivot Point 0.73 0.73 0.73 0.73 0.73
Support 1 (S1) 0.70 0.71 0.69 0.70 0.67
Support 2 (S2) 0.68 0.70 0.68 0.67
Support 3 (S3) 0.65 0.68 0.66
Support 4 (S4) 0.65